Clinical trials: Arterial Disease
Peripheral Arterial Disease
A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)
Randomized multicenter clinical trial consisting of two arms; one arm treated with PTA plus the MicroStent® System and one arm treated with PTA alone.
- Trial name
- STAND (NCT03477604)
- Testing
- MicroStent and Standard PTA, Standard PTA
- Where
- 21 sites in United States
- Volunteers
- 177 people
- Sponsor
- Micro Medical Solution, Inc.
Cardiovascular Disease, Arterial Stiffness
Natural History Study of CADASIL
Background: CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy) is a genetic disorder. It causes narrowing of the small blood vessels and can lead to strokes and dementia.
- Conditions
- Cardiovascular Disease, Arterial Stiffness, Germline Mutation in the NOTCH 3 Gene, Pathogenesis of CADASIL
- Trial name
- NCT05072483
- Testing
- MRI
- Where
- United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).
- Trial name
- ROCSTAR (NCT07175038)
- Testing
- ROC-101
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AllRock Bio, Inc.
Peripheral Arterial Disease
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial disease (PAD). Participation in the study will last about 58 weeks.
- Trial name
- ATTAIN-PAD (NCT07223593)
- Testing
- Orforglipron
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 1,205 people
- Sponsor
- Eli Lilly and Company
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise
The study aim is to monitor, during exercise tests carried out in various conditions, the alveolar dead space, by means of continuous transcutaneous measurement of Pt CO2, which would be used as a surrogate for arterial PaCO2.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Chronic Heart Failure, Pulmonary Arterial Hypertension
- Trial name
- TEASE (NCT03718780)
- Testing
- simultaneous determination of PaCO2 and PtCO2, Hyperventilation test, Exercise test
- Where
- 4 sites in France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Metropole Savoie
Ischemia, Cerebral, Ischemic Stroke
Detection of Cerebral Ischemia With Artificial Intelligence.
In patients undergoing planned surgery for carotid tromendarterendectomy, a non-invasive device that registers heart rate variability is attached.
- Conditions
- Ischemia, Cerebral, Ischemic Stroke, Artery Occlusion, Artery Carotid Stenosi
- Trial name
- CIDAI-BAS (NCT03919370)
- Testing
- No intervention
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Linda Block
Coronary Arterial Disease (CAD)
The Switching Antiplatelet-9 (SWAP-9) Study
The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).
- Trial name
- SWAP-9 (NCT06588595)
- Testing
- Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
The primary aim of this study is to investigate the PD effects of switching from standard-dose clopidogrel dose to low-dose prasugrel versus continuing standard-dose clopidogrel in patients at dual-risk (HBR defined as the…
- Trial name
- NCT07025148
- Testing
- Prasugrel, Clopidogrel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Florida
Femoropopliteal Disease, Drug Coated Balloon
DCB Outcomes After Non-Compliant Balloon Vessel Preparation With or Without Scoring in Patients With Femoropopliteal Arterial Disease
The aim of this clinical trial is to determine whether vessel preparation with a non-compliant scoring balloon before drug-coated balloon (DCB) angioplasty provides superior procedural and clinical outcomes compared with vessel…
- Conditions
- Femoropopliteal Disease, Drug Coated Balloon, Critical Limb-Threatening Ischaemia, Peripheral Arterial Disease
- Trial name
- DASBAD-NC (NCT07764016)
- Testing
- Non-compliant Plain Balloon angioplasty (PBA), Non-compliant Scoring Balloon Angioplasty (SB)
- Volunteers
- 142 people
- Sponsor
- Marc Sirvent
PAH, Pulmonary Hypertension
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03683186
- Testing
- Ralinepag
- Where
- 190 sites in United States, Argentina and 31 more
- Volunteers
- 1,000 people
- Sponsor
- United Therapeutics
Peripheral Artery Occlusive Disease
Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit Early Feasibility Study
A prospective, single arm, non-randomized early feasibility study to evaluate the preliminary safety and performance of the XPAD conduit in patients with peripheral arterial occlusive disease (PAOD), scheduled to undergo elective…
- Trial name
- NCT06951685
- Testing
- Xeltis Peripheral Artery Disease (XPAD) Bypass Conduit
- Where
- Costa Rica
- Volunteers
- 6 people
- Sponsor
- Xeltis
Peripheral Arterial Disease
Hemodynamic Characteristics of Peripheral Arterial Disease Using Computational Fluid Dynamics
Peripheral arterial disease can reduce blood flow to the legs. This study will examine how blood flow patterns in the leg arteries differ between people with peripheral arterial disease and people without the disease.
- Trial name
- NCT07860138
- Testing
- Computational Fluid Dynamics Simulation
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Fudan University
Peripheral Arterial Disease, Atherosclerosis of Extremities
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with…
- Conditions
- Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation
- Trial name
- LEADER-PAD (NCT04774159)
- Testing
- Colchicine 0.5 MG Oral Tablet
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 6,150 people
- Sponsor
- Population Health Research Institute
Aneurysm Abdominal, Peripheral Arterial Disease
Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression
The VASCULAID-RETRO study, within the broader VASCULAID project, aims to create artificial intelligence (AI) algorithms that can predict cardiovascular events and the progression of abdominal aortic aneurysm (AAA) and peripheral…
- Trial name
- VASCULAIDRETRO (NCT06206369)
- Testing
- No intervention, retrospective study
- Where
- 6 sites in Finland, Germany and 4 more
- Volunteers
- 11,000 people
- Sponsor
- Amsterdam UMC, location VUmc
Peripheral Artery Disease, Intermittent Claudication
Improving Mobility After Revascularization in Peripheral Artery Disease
Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia.
- Conditions
- Peripheral Artery Disease, Intermittent Claudication, Peripheral Vascular Disease, Mobility Limitation
- Trial name
- IMPACT PAD (NCT06686121)
- Testing
- Home Based Exercise, Nitrate Rich Beetroot Juice, Attention Control
- Where
- 8 sites in United States
- Volunteers
- 386 people
- Sponsor
- Northwestern University
Peripheral Arterial Disease
Exoskeleton Footwear to Improve Walking
The purpose of this study is to determine the best assistance level of an exoskeleton footwear (EF) that can assist walking for people older than 40 with and without peripheral artery disease (PAD).
- Trial name
- NCT04337554
- Testing
- Exoskeleton footwear
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Peripheral Artery Disease, Claudication, Intermittent
Passive Calf Stretching Therapy in Peripheral Artery Disease
The goal of this clinical trial is to assess the effects of passive calf muscle stretching in patients diagnosed with peripheral artery disease (PAD). The main question it aims to answer are: 1.
- Trial name
- NCT06041880
- Testing
- Passive calf muscle stretching device
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Penn State University
Coronary Arterial Disease (CAD)
Reconsidering Long-Term Apirin in the Elderly in Secondary Prevention of Coronary Artery Disease Norway
Lifelong aspirin has been a cornerstone of secondary prevention after coronary artery disease (CAD), based on trials conducted 40-50 years ago.
- Trial name
- RELEASE-Norway (NCT07854795)
- Testing
- Discontinuation of aspirin (ATC-code B01AC06 and N02BA01)
- Where
- 9 sites in Norway
- Volunteers
- 7,000 people
- Sponsor
- Vestre Viken Hospital Trust
Obliterans, Arteriosclerosis, Peripheral Arterial Disease
Combined Treatment for Non-Healing Wounds in Chronic Lower Extremity Arterial Disease: A Comparative Study
Endovascular interventions, such as balloon angioplasty and stenting, are commonly used for PAD due to their proven safety and effectiveness. However, traditional treatments for chronic non-healing wounds are often insufficient.
- Conditions
- Obliterans, Arteriosclerosis, Peripheral Arterial Disease, Diabetic Foot
- Trial name
- NCT06724276
- Testing
- balloon angioplasty and stenting of lower extremity vessels + fibroblasts, balloon angioplasty and stenting of lower extremity vessels
- Where
- Kazakhstan
- Volunteers
- 116 people
- Sponsor
- Tulip Medicine